Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 5, 2026, 1:18 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 673–696 of 9,944 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Infectious Clear all

Conditions: Hepatitis C, Chronic, Pregnancy; Infection
Interventions: Sofosbuvir/Velpatasvir 400 MG-100 MG Oral Tablet; Drug
Lead sponsor: Catherine Anne Chappell; Other
Eligibility: 18 Years to 45 Years · Female only
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2027
U.S. locations: 6
States / cities: Cincinnati, Ohio • Columbus, Ohio • Pittsburgh, Pennsylvania + 3 more

Conditions: Parenteral Nutrition
Interventions: ClinOleic 20% Intravenous Emulsion, Intralipid, 20% Intravenous Emulsion; Drug
Lead sponsor: Emory University; Other
Eligibility: 18 Years to 80 Years
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2010
U.S. locations: 2
States / cities: Atlanta, Georgia

Conditions: Onychomycosis
Interventions: AN2690; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2007
U.S. locations: 1
States / cities: Bryan, Texas

Conditions: HIV Infections
Interventions: HIV-1 C4-V3 Polyvalent Peptide Vaccine; Biological
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 50 Years
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Ends 2002
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Infection, Meningitis
Interventions: Not listed
Lead sponsor: IDbyDNA, Inc.; Industry
Eligibility: 0 Years to 17 Years
Enrollment: 71 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2020
U.S. locations: 3
States / cities: Orange, California • San Diego, California • Miami, Florida

Conditions: HIV/AIDS, Medication Adherence
Interventions: Proteus digital health feedback (PDHF) system; Device
Lead sponsor: University of California, Los Angeles; Other
Eligibility: 17 Years and older
Enrollment: 130 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2020
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Fractures, Open
Interventions: Tobramycin, Placebo: normal saline; Drug · Other
Lead sponsor: University of Virginia; Other
Eligibility: 18 Years to 70 Years
Enrollment: 11 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2019
U.S. locations: 1
States / cities: Charlottesville, Virginia

Conditions: SARS-CoV-2 Infection, COVID-19
Interventions: Molnupiravir 200 mg, Molnupiravir 400 mg, Molnupiravir 800 mg, Placebo (PBO); Drug
Lead sponsor: Ridgeback Biotherapeutics, LP; Industry
Eligibility: 18 Years and older
Enrollment: 204 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2021
U.S. locations: 10
States / cities: Northridge, California • Oxnard, California • Yucaipa, California + 7 more

Conditions: Hepatitis C, Chronic; AUD
Interventions: Brief alcohol counseling, Group and Individual Therapy Sessions; Behavioral
Lead sponsor: Duke University; Other
Eligibility: 18 Years and older
Enrollment: 182 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2018
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: HIV Infections
Interventions: Indinavir sulfate, Ritonavir; Drug
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
U.S. locations: 8
States / cities: Los Angeles, California • Miami, Florida • Chicago, Illinois + 5 more

Conditions: Respiratory Syncytial Virus Infection
Interventions: Clesrovimab, Placebo; Biological · Drug
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: Up to 1 Year
Enrollment: 3,632 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2024
U.S. locations: 51
States / cities: Dothan, Alabama • Fayetteville, Arkansas • Jonesboro, Arkansas + 45 more

Conditions: Granuloma, Granulomatous Disease, Chronic, Leukocyte Disease, Genetic Disease, X-Linked, Genetic Disease, Inborn
Interventions: Not listed
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 70 Years
Enrollment: 850 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: Started 1994
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Clostridium Difficile Infection
Interventions: Fecal Microbiota Transplant; Drug
Lead sponsor: Methodist Health System; Other
Eligibility: Not listed
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2022
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: HIV Infections
Interventions: Potent HAART during acute or early HIV-1 infection; Drug
Lead sponsor: Rockefeller University; Other
Eligibility: 18 Years and older
Enrollment: 12 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2003 – 2005
U.S. locations: 1
States / cities: New York, New York

Conditions: Influenza
Interventions: 40 mg Laninamivir Octanoate, 80 mg Laninamivir Octanoate, Placebo; Drug
Lead sponsor: Biota Scientific Management Pty Ltd; Industry
Eligibility: 18 Years to 64 Years
Enrollment: 639 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2014
U.S. locations: 70
States / cities: Scottsboro, Alabama • Camp Verde, Arizona • Chandler, Arizona + 59 more

Conditions: HIV Infections
Interventions: Indinavir sulfate, Lamivudine/Zidovudine, Nelfinavir mesylate, Efavirenz; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 13 Years and older
Enrollment: 444 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Ends 2001
U.S. locations: 49
States / cities: Birmingham, Alabama • Los Angeles, California • Palo Alto, California + 32 more

Conditions: HIV
Interventions: PRO 140 (350 mg), PRO 140 (525 mg), PRO 140 (700 mg); Drug
Lead sponsor: CytoDyn, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 562 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2020
U.S. locations: 12
States / cities: La Mesa, California • Palm Springs, California • San Francisco, California + 9 more

Conditions: Uveitis, Posterior
Interventions: Fluocinolone Acetonide Intravitreal Implant 0.18 mg; Drug
Lead sponsor: Alimera Sciences; Industry
Eligibility: 18 Years and older
Enrollment: 125 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2025
U.S. locations: 23
States / cities: Fullerton, California • Glendale, California • Pasadena, California + 20 more

Conditions: Healthy, West Nile Fever, Healthy Volunteer, HV
Interventions: VRC-WNVDNA017-00-VP; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 50 Years
Enrollment: 15 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2005 – 2008
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Tinea Pedis, Tinea Cruris
Interventions: NAFT500 (pediatric), NAFT600 (pediatric), NAFT500 (adult), NAFT600 (adult); Drug
Lead sponsor: Merz North America, Inc.; Industry
Eligibility: 12 Years to 65 Years
Enrollment: 56 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2013
U.S. locations: 2
States / cities: Austin, Texas • College Station, Texas

Conditions: Hidradenitis Suppurativa
Interventions: Fecal Microbiota - lyophilized, Placebo drug; Drug
Lead sponsor: University of Minnesota; Other
Eligibility: 18 Years and older
Enrollment: 16 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2026
U.S. locations: 1
States / cities: Minneapolis, Minnesota

Conditions: Surgical Site Infection
Interventions: Chlorhexidine-alcohol group, Povidone-Iodine Group; Drug
Lead sponsor: Brigham and Women's Hospital; Other
Eligibility: 18 Years to 45 Years · Female only
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2017
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: HIV Infections
Interventions: MVA-mBN120B; Biological
Lead sponsor: Bavarian Nordic; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2009
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: HIV Infections
Interventions: Globulin, Immune, Zidovudine; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 3 Months to 12 Years
Enrollment: 250 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Ends 1993
U.S. locations: 48
States / cities: Downey, California • Long Beach, California • Los Angeles, California + 29 more

Search by objective public record fields.

Sofosbuvir/Velpatasvir Treatment of Chronic Hepatitis C During Pregnancy

Study Comparing a Soybean Oil-Based With an Olive Oil-Based Lipid Emulsion in ICU Patients Requiring TPN

Absorption and Systemic Study of AN2690 in Patients With Moderate to Severe Onychomycosis (ADME I)

A Phase I Trial of HIV-1 C4-V3 Polyvalent Peptide Vaccine in HIV-1 Infected Persons

Pediatric Infectious Disease Precision Medicine Using Sequencing Evaluation of CSF

Measuring and Monitoring Adherence to ART With Pill Ingestible Sensor System

Locally Applied Antibiotics for Infection Prophylaxis in Treatment of Open Fractures

Safety, Tolerability and Efficacy of Molnupiravir (EIDD-2801) to Eliminate Infectious Virus Detection in Persons With COVID-19

Hepatitis C Alcohol Reduction Treatment

Safety and Effectiveness of an Anti-HIV Drug Combination in HIV-Positive Patients Who Have Failed Previous Treatment With Protease Inhibitors

Efficacy and Safety of Clesrovimab (MK-1654) in Infants (MK-1654-004)

Recruitment and Apheresis Collection of Peripheral Blood Hematopoietic Stem Cells, Mononuclear Cells and Granulocytes

Fecal Microbiota Transplant

Phase I/II, Open-Label Trial of Three Monoclonal Antibodies

Efficacy and Safety Study of Laninamivir Octanoate TwinCaps® Dry Powder Inhaler in Adults With Influenza

Addition of Efavirenz or Nelfinavir to a Lamivudine/Zidovudine/Indinavir HIV Treatment Regimen

Study of PRO 140 SC as Single Agent Maintenance Therapy in Virally Suppressed Subjects With CCR5-tropic HIV-1 Infection

Fluocinolone Acetonide Intravitreal Implant 0.18 mg in the Treatment of Chronic Non-Infectious Posterior Segment Uveitis

Vaccine to Prevent West Nile Virus Disease

Pharmacokinetic Study of Pediatric Subjects With Tinea Cruris and Tinea Pedis

Capsule Microbiota Transplant Therapy for Hidradenitis Suppurativa

Prevention of Surgical Site Infection After Cesarean Delivery

Phase I Safety Study of a Recombinant MVA HIV Multiantigen Vaccine in HIV-infected Subjects

A Double-Blind, Placebo-Controlled Trial To Evaluate Intravenous Gamma Globulin in Children With Symptomatic HIV Infection Receiving Zidovudine